Correlative Study Of Expressions Of LASP-1Protein And Human Brain Astrocytoma

Objective:1.To investigate the relationship between expressions of LASP-1proteinand human brain astrocytoma.2.To investigate the relationship between expressions of LASP-1proteinand the malignant degree of human brain astrocytoma.Methods:1.The immunohistochemical SP staining method was used to detection forexpresses and the malignant degree of LASP-1protein in human brainastrocytoma.The cases of high-grade(WHOⅢ-Ⅳ) and low-grade(WHOⅠ-Ⅱ) malignantgroup of astrocytoma and the control group were25、25、10respectively.Tumors group: The human brain astrocytoma specimens of paraffin werecollected,which were surgically treated for the first time in ourdepartment form July2007to December2013.and all patients did notreceive radiation and chemo-therapy before surgery.Control group:The human normal brain tissue came from operation oftraumatic brain injury, hypertensive cerebral hemorrhage in ourdepartment form May2013to December2013.The pathology department of our hospital provide for4μm thick paraffinsections.2.The Western Blot method was used to determination for expresses and themalignant degree of LASP-1protein in human brain astrocytoma.The cases of high-grade(WHOⅢ-Ⅳ) and low-grade(WHOⅠ-Ⅱ) malignantgroup of astrocytoma and the control group were20、20、10respectively.Tumors group:The human brain astrocytoma specimens of paraffin werecollected,which were surgically treated for the first time in ourdepartment form October2011to February2014.and all patients did notreceive radiation and chemo-therapy before surgery. Control group:The human normal brain tissue came from operation oftraumatic brain injury, hypertensive cerebral hemorrhage in ourdepartment form May2013to December2013.Results:1.The immunohistochemical SP staining showed that LASP-1protein expressbetween astrocytoma tissue and human normal tissue.50cases of brainastrocytoma specimens and10cases of normal brain tissue of the averagepositive rate were0.6052±0.2046and0.2285±0.0493respectively.Theresults showed that there were high expresses of LASP-1protein (positiverate from tumor group to that from Control group) in astrocytoma group,and the difference was statistically significant (t=11.459, p<0.01).25cases of high-grade malignant astrocytoma (WHOⅢ-Ⅳ) and25cases oflow-grade malignant astrocytoma (WHOⅠ-Ⅱ) specimens of the averagepositive rate were0.7838±0.1307and0.4266±0.0437respectively.Theresults showed that there were high expresses of LASP-1protein (positiverate from high-grade malignant astrocytoma group to that from low-grademalignant astrocytoma group) in high-grade malignant astrocytomagroup,and there was statistically significant among the groups(t=12.953,p<0.01).2.The result of western blotting showed that LASP-1protein expressbetween astrocytoma tissue and human normal tissue.40cases of brainastrocytoma specimens and10cases of normal brain tissue of the averagegray ratio of lasp1/β-actin were0.6787±0.1085and0.3781±0.0509respectively.The results showed that there were high expresses of LASP-1protein (positive rate from tumor group to that from Control group) inastrocytoma group, and the difference was statistically significant(t=12.775，P<0.01).20cases of high-grade malignant astrocytoma(WHOⅢ-Ⅳ) and20cases oflow-grade malignant astrocytoma (WHOⅠ-Ⅱ) specimens of the average gray ratio of lasp1/β-actin were0.7765±0.0415and0.5808±0.0475respectively.The results showed that there were high expresses of LASP-1protein (positive rate from high-grade malignant astrocytoma group tothat from low-grade malignant astrocytoma group) in high-grade malignantastrocytoma group,and there was statistically significant among thegroups (t=13.896，P<0.01).Conclusion:1.LASP-1protein was expressed in human brain astrocytoma and brainnormal tissue.and it was highly expressed in human brain astrocytoma.2.The expression of LASP-1protein increased with the increased ofpathology grade of astrocytoma.3.The expression of LASP-1protein may act as marker in evaluatingmalignancy of astrocytoma patients.and it may be a new target forastrocytoma therapy.